Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

FORGOTTEN HISTORY: 19 - The Untold Story

FDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines

Government advisers say it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall

The Independent UK · Jun 5, 2024

Should You Buy This S&P 500 Stock with a Dividend Yield of Nearly 6%?

With a dividend yield of nearly 6%, pharma giant Pfizer is among the highest-yielding S&P 500 stocks. While the stock's price action has been disappointing like most other high-dividend stocks, it looks worth a bet given the tepid valuations.

Barchart · Jun 4, 2024

Only 49 companies have been on the Fortune 500 for all 70 years. Here are their secrets to staying in power

Prolonged success boils down to a few subtle factors—but surprisingly, they don't include strategy, structure, technology, or even culture.

Fortune · Jun 4, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Bird flu vaccines face a problem: eggs

Fertilized hen eggs are still the main ingredient in making vaccines that may protect us against H5N1

Salon · Jun 1, 2024

Scientists are testing mRNA vaccines to protect cows and people against bird flu

The bird flu outbreak in U.S. dairy cows is prompting development of new, next-generation mRNA vaccines — akin to the shots deployed during the COVID-19 pandemic

The Independent UK · May 31, 2024

Strong Trial Results For Pfizer Lung Cancer Drug

A Pfizer medicine has been shown to greatly reduce cancer progression and improve survival outcomes for people in the advanced stages of a form of lung cancer, results published Friday showed.

International Business Times · May 31, 2024

Guillain-Barre Syndrome 'More Common Than Expected' In RSV Vaccinated Older Adults: CDC

While the U.S. Food and Drug Administration (FDA) and the officials from the CDC continue to investigate the risks, the current recommendation is to continue the vaccine as "the estimated benefits of RSV vaccination continued to outweigh potential risks."

Medical Daily · May 31, 2024

Read news from The Economist, FT, and more,
with one subscription

CDC Reports Rare Nervous System Disorder In RSV Vaccine

CDC reports increased Guillain-Barre syndrome cases in older adults post-RSV vaccination, emphasizing benefits outweigh risks.

Guillain-Barre syndrome 'more common than expected' with RSV vaccine in older people, CDC reiterates

Reports of a rare nervous system disorder are “more common than expected” in older U.S. adults who got the new RSV vaccines

The Independent UK · May 30, 2024

Dividend Stability and Growth in Pharma: Pfizer (PFE) vs. Bristol-Myers Squibb (BMY)

The pharma sector is primed for solid growth owing to technological advancements, growing healthcare needs, and a rise in chronic diseases. Given this backdrop, let’s analyze the fundamentals of pharmaceutical stocks Pfizer (PFE) and Bristol-Myers Squibb (BMY) to determine which of these stocks offer better dividend stability and growth. Read…

StockNews.com · May 28, 2024

Will AstraZeneca be the UK’s first £200bn company?

The former pharma laggard is in a race with Shell to be the first FTSE 100 stock to be valued at £200bn

The Guardian - UK · May 21, 2024

5 Standout Healthcare Dividend Stocks to Consider Now

Amid healthcare’s enduring importance and increasing demand for its products and services, here are five dividend-paying healthcare stocks to consider now.

Barchart · May 11, 2024

Pfizer reports patient death in Duchenne gene therapy study

Pfizer's gene therapy trial for Duchenne muscular dystrophy resulted in a young patient's death from cardiac arrest

The Hindu · May 8, 2024

2 Covered Call Ideas on Pfizer Stock

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start.

Barchart · May 7, 2024

Get all your
news in one place.

100's of premium titles.
One news app.

Reason · May 6, 2024

Missouri Bill Would Ban Eminent Domain, but Only for Wind and Solar Projects

The Show Me State has plenty of room to rein in laws on taking private property, but instead, lawmakers are focusing only on one very narrow use case.

StockNews.com · May 3, 2024

Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

Latin Times · May 2, 2024

Pfizer Profits Drop On Lower Covid-19 Product Sales

Much lower sales of Covid-19 vaccine Comirnaty and therapeutic Paxlovid accounted for a 20 percent drop in first-quarter revenues to $14.9 billion compared with the year-ago period.

International Business Times · May 1, 2024

Pfizer Profits Drop On Lower Covid-19 Product Sales

Pfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and implements previously announced cost cuts.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart · May 1, 2024

Stock Index Futures Slip as Investors Await Fed Rate Decision, U.S. PMI and Jobs Data on Tap

June S&P 500 E-Mini futures (ESM24) are down -0.42%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.73% this morning as mixed earnings and the prospect of higher-for-longer U.S. interest rates weighed on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.

Barchart · May 1, 2024

Stock Index Futures Slip as Fed Rate Decision Looms, U.S. Jobs Data on Tap

June S&P 500 E-Mini futures (ESM24) are down -0.29%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.58% this morning as the prospect of higher-for-longer U.S. interest rates continued to weigh on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.

Barchart · May 1, 2024

Stock Index Futures Slip as Investors Await Fed Rate Decision, U.S. Jobs Data on Tap

Barchart · Apr 16, 2024

5 Underperforming Stocks That Look Ready to Rebound, According to Goldman

Analysts at Goldman Sachs think these 5 underperforming stocks could be poised to outperform, thanks to a healthy valuation discount and expected EPS growth.

WEKU · Apr 15, 2024

Drugmakers' low U.S. taxes belie their high sales

Most of the largest pharmaceutical companies report losing money in the United States, despite the majority of their sales coming from Americans. The result is lower U.S. taxes for the companies.

AAP · Apr 11, 2024

Most at-risk Aussies don't have COVID-19 plan with a GP

Some 75 per cent of Australians at higher risk of serious illness from COVID-19 do not have a plan to manage the potentially-lethal virus, new research shows.

Barchart · Apr 11, 2024

2 Defensive Stocks to Buy Now as 'Higher For Longer' Woes Rattle Markets

U.S. stocks fell yesterday as the 10-year Treasury yield rose above 4.5% amid sticky inflation. As markets turn volatile, Pfizer and Apple look like two defensive names worth considering.

1 … 18 19 20 21

Coverage From

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.